Patents by Inventor Jeremy P. W. Heaton
Jeremy P. W. Heaton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20020193307Abstract: The mechanism of hypertension following acute NO synthase blockade is via endothelin-mediated vasoconstriction. Thus, NO appears to inhibit endothelin activity by blocking its expression and not as a chronic direct acting vasodilator. Administration of an endothelin antagonist to a patient in a ‘normal’ physiological state may result in specific regional vasodilation. This treatment finds utility in the treatment of erectile dysfunction.Type: ApplicationFiled: March 11, 2002Publication date: December 19, 2002Applicant: Queen's University at KingstonInventors: James D. Banting, Jeremy P.W. Heaton, Michael A. Adams
-
Publication number: 20020193442Abstract: The present invention provide a method of treating sexual dysfunction in a female, including the vasculogenic symptoms of delayed vaginal engorgement, diminished vaginal lubrication, pain or discomfort with intercourse (dyspareunia), diminished vaginal sensation, diminished vaginal orgasm, diminished clitoral sensation or diminished clitoral orgasm, or of combating vaginal pain by stimulating peripheral pelvic nerve release of nitric oxide (NO). The method comprises administering to a female in need of such treatment a therapeutically effective amount of a compound which acts on a mid-brain pathway to increase blood flow to the ilio-hypogastric-pudendal artery bed and stimulate the release of nitric oxide (NO) from peripheral NANC nerve cells. The preferred compound for the method of this invention is apomorphine or one of its pharmaceutically acceptable salts, esters, or pro-drugs.Type: ApplicationFiled: April 22, 2002Publication date: December 19, 2002Inventors: Jeremy P. W. Heaton, Michael A. Adams
-
Publication number: 20020165122Abstract: The present invention provide a method of treating sexual dysfunction in a female, including the vasculogenic symptoms of delayed vaginal engorgement, diminished vaginal lubrication, pain or discomfort with intercourse (dyspareunia), diminished vaginal sensation, diminished vaginal orgasm, diminished clitoral sensation or diminished clitoral orgasm, or of combating vaginal pain by stimulating peripheral pelvic nerve release of nitric oxide (NO). The method comprises administering to a female in need of such treatment a therapeutically effective amount of a compound which acts on a mid-brain pathway to increase blood flow to the ilio-hypogastric-pudendal artery bed and stimulate the release of nitric oxide (NO) from peripheral NANC nerve cells. The preferred compound for the method of this invention is apomorphine or one of its pharmaceutically acceptable salts, esters, or pro-drugs.Type: ApplicationFiled: May 2, 2002Publication date: November 7, 2002Inventors: Jeremy P. W. Heaton, Michael A. Adams
-
Patent number: 6458797Abstract: The present invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a method of ameliorating or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudendal arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent. The anti-pressor agent comprises one or more compounds selected from the therapeutic classes of direct vasodilators such as hydralazine and NO donors, ACE inhibitors, angiotensin-II receptor antagonists, &agr;1-adrenergic receptor antagonists, &bgr;-adrenergic receptor antagonists, calcium channel blockers, and phosphodiesterase inhibitors.Type: GrantFiled: July 12, 2001Date of Patent: October 1, 2002Assignee: Queen's University of KingstonInventors: Michael A. Adams, Jeremy P. W. Heaton
-
Publication number: 20020106634Abstract: A method for diagnosing hypoxia, endothelial dysfunction, a vascular or circulatory condition of a subject, in which the level of expression of a gene, and/or the level of a metabolite or metabolic by-product in a biological test sample is measured and compared to a control sample so as to assess the vascular condition of the subject, is described.Type: ApplicationFiled: January 29, 2002Publication date: August 8, 2002Inventors: Michael A. Adams, Jeremy P.W. Heaton, Charles H. Graham
-
Patent number: 6423683Abstract: Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (½ to {fraction (1/20)}) of those known to induce vasodilation in “normal” circulations.Type: GrantFiled: July 11, 2000Date of Patent: July 23, 2002Assignee: Queens University at KingstonInventors: Jeremy P. W. Heaton, Michael A. Adams, James D. Banting
-
Publication number: 20020091088Abstract: Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (½ to {fraction (1/20)}) of those known to induce vasodilation in “normal” circulations.Type: ApplicationFiled: March 8, 2002Publication date: July 11, 2002Applicant: Queen's University at KingstonInventors: Jeremy P.W. Heaton, Michael A. Adams, James D. Banting
-
Patent number: 6410007Abstract: The mechanism of hypertension following acute NO synthase blockage is via endothelin-mediated vasoconstriction. Thus, NO appears to inhibit endothelin activity by blocking its expression and not as a chronic direct acting vasodilator. Administration of an endothelin antagonist to a patient in a ‘normal’ physiological state may result in specific regional vasodilation. This treatment finds utility in the treatment of erectile dysfunction.Type: GrantFiled: September 14, 1998Date of Patent: June 25, 2002Assignee: Queen's University at KingstonInventors: James D. Banting, Jeremy P. W. Heaton, Michael A. Adams
-
Patent number: 6403605Abstract: The present invention provides, in one embodiment, a method of normalizing the timing of sexual response in a mammal comprising the administration of an amount of a central nervous system sexual response initiator in an amount sufficient to produce genital vasodilation but less than the amount required to produce effective vasocongestive arousal. The method is applicable not only to adjusting or normalizing the timing of sexual response in humans, but in the breeding of valuable commercial animals such as horses, cattle, sheep, swine and the like and domesticated pets such as dogs and go cats. In an alternative embodiment, the present invention provides a method for the prophylactic treatment of long-term tissue degradation in the genital organs comprising the administration to a mammal of a central nervous system sexual response initiator in an amount sufficient to produce genital vasodilation but less than the amount required to produce effective vasocongestive arousal.Type: GrantFiled: May 29, 1998Date of Patent: June 11, 2002Assignee: Queen's University at KingstonInventors: Jeremy P. W. Heaton, Michael A. Adams
-
Patent number: 6395744Abstract: The present invention provide a method of treating sexual dysfunction in a female, including the vasculogenic symptoms of delayed vaginal engorgement, diminished vaginal lubrication, pain or discomfort with intercourse (dyspareunia), diminished vaginal sensation, diminished vaginal orgasm, diminished clitoral sensation or diminished clitoral orgasm, or of combating vaginal pain by stimulating peripheral pelvic nerve release of nitric oxide (NO). The method comprises administering to a female in need of such treatment a therapeutically effective amount of a compound which acts on a mid-brain pathway to increase blood flow to the ilio-hypogastric-pudendal artery bed and stimulate the release of nitric oxide (NO) from peripheral NANC nerve cells. The preferred compound for the method of this invention is apomorphine or one of its pharmaceutically acceptable salts, esters, or pro-drugs.Type: GrantFiled: June 18, 1999Date of Patent: May 28, 2002Assignee: Queen's University at KingstonInventors: Michael A. Adams, Jeremy P. W. Heaton
-
Patent number: 6376169Abstract: A method for diagnosing hypoxia, endothelial dysfunction, a vascular or circulatory condition of a subject, in which the level of expression of a gene, and/or the level of a metabolite or metabolic by-product in a biological test sample is measured and compared to a control sample so as to assess the vascular condition of the subject, is described.Type: GrantFiled: April 30, 1999Date of Patent: April 23, 2002Assignee: Queens University at KingstonInventors: Michael A. Adams, Jeremy P. W. Heaton, Charles H. Graham, Susan E. Brien
-
Publication number: 20020040059Abstract: Methods and formulations for inhibiting and preventing a malignant cell phenotype by administering to cells a low dose of a nitric oxide mimetic are provided.Type: ApplicationFiled: April 26, 2001Publication date: April 4, 2002Inventors: Michael A. Adams, Charles H. Graham, Jeremy P.W. Heaton, Lynne-Marie Postovit
-
Publication number: 20020035067Abstract: The present invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a method of ameliorating or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudendal arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent. The anti-pressor agent comprises one or more compounds selected from the therapeutic classes of direct vasodilators such as hydralazine and NO donors, ACE inhibitors, angiotensin-II receptor antagonists, &agr;1-adrenergic receptor antagonists, &bgr;-adrenergic receptor antagonists, calcium channel blockers, and phosphodiesterase inhibitors.Type: ApplicationFiled: July 12, 2001Publication date: March 21, 2002Inventors: Michael A. Adams, Jeremy P.W. Heaton
-
Publication number: 20020015740Abstract: Methods and compositions for improving sleep in individuals with sleep disorders or other conditions which interfere with normal sleep via administration of a NO-mimetic are provided.Type: ApplicationFiled: February 22, 2001Publication date: February 7, 2002Inventors: C. Bruce Ackman, Michael A. Adams, Jeremy P.W. Heaton, Jodan D. Ratz
-
Publication number: 20010039257Abstract: In the field of treatment of erectile dysfunction there is disclosed a novel therapy in which the actions of an agent or agents, produce a combination of effects to induce effective erection (and avoid priapism) while reducing or entirely avoiding pain. The method taught combines a first action of an agent which is to antagonize a drug-induced pain stimulus within nociceptive nerves of penile tissue with a second action of either the same agent or of a second agent, which enhances, synergistically, smooth muscle relaxation. The synergism allows for at least an equivalent effect of smooth muscle relaxation to be obtained at significantly lower doses of a smooth muscle relaxing agent such as PGE1 which in standard therapy is also in 40-45% of cases pain-inducing at doses which achieve effective erection.Type: ApplicationFiled: October 23, 1998Publication date: November 8, 2001Inventors: MICHAEL A. ADAMS, JEREMY P. W. HEATON, DONALD H. MAURICE
-
Patent number: 6284763Abstract: The present invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a method of ameliorating or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudendal arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent. The anti-pressor agent comprises one or more compounds selected from the therapeutic classes of direct vasodilators such as hydralazine and NO donors, ACE inhibitors, angiotensin-II receptor antagonists, &agr;1-adrenergic receptor antagonists, &bgr;-adrenergic receptor antagonists, calcium channel blockers, and phosphodiesterase inhibitors.Type: GrantFiled: August 25, 1999Date of Patent: September 4, 2001Assignee: Queen's University at KingstonInventors: Michael A. Adams, Jeremy P. W. Heaton
-
Patent number: 6200288Abstract: An everting toroid for use in delivering a powdered, fluid, or aerosolized pharmaceutical composition, or other composition, to an internal body cavity, such as the urethra, or other cavity, is contained within a tubular housing and may be extended therefrom and retracted back into the tubular housing. The composition may be distributed on the surface of the everting toroid when made from an impermeable membrane, contained within the toroid when made from a permeable membrane, or may be injected through the lumen thereof via an aerosol wand which releases the composition as the toroid and/or wand are withdrawn from the cavity.Type: GrantFiled: January 29, 1999Date of Patent: March 13, 2001Assignee: Queen's University at KingstonInventors: Jeremy P. W. Heaton, Michael A. Adams, James D. Banting
-
Patent number: 6200983Abstract: Psychogenic impotence or erectile dysfunction can be identified in psychogenic male patients and can be ameliorated, without substantial undesirable side effects, by sublingual administration of apomorphine dosage forms so as to maintain a plasma concentration of apomorphine of no more than about 5.5 nanograms per milliliter.Type: GrantFiled: November 15, 1999Date of Patent: March 13, 2001Assignees: Pentech Pharmaceuticals, Inc., Queen's University at KingstonInventors: Ragab El-Rashidy, Jeremy P. W. Heaton, Alvaro Morales, Michael A. Adams
-
Patent number: 6165975Abstract: A method of treatment, in an organism, of a vascular condition, comprising administration of at least one agent at a level which enhances NO and which does not appreciably alter normal systemic vascular tone in said organism. At least one agent is an NO donor selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine molsidomine, S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, and N-hydroxy-L-arginine.Type: GrantFiled: December 22, 1999Date of Patent: December 26, 2000Assignee: Queen's University at KingstonInventors: Michael A. Adams, Jeremy P. W. Heaton, James D. Banting
-
Patent number: 5985889Abstract: Psychogenic impotence or erectile dysfunction can be identified in psychogenic male patients and can be ameliorated, without substantial undesirable side effects, by sublingual administration of apomorphine dosage forms so as to maintain a plasma concentration of apomorphine of no more than about 5.5 nanograms per milliliter.Type: GrantFiled: June 22, 1998Date of Patent: November 16, 1999Assignees: Pentech Pharmaceuticals, Inc., Queen's University at KingstonInventors: Ragab El-Rashidy, Jeremy P. W. Heaton, Alvaro Morales, Michael A. Adams